Can Fite Biofarma (Can Fite Biofarma) Days Sales Outstanding

: 0.00 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

Can Fite Biofarma's average Accounts Receivable for the three months ended in Dec. 2023 was $0.00 Mil. Can Fite Biofarma's Revenue for the three months ended in Dec. 2023 was $0.16 Mil. Hence, Can Fite Biofarma's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Can Fite Biofarma's Days Sales Outstanding or its related term are showing as below:

During the past 13 years, Can Fite Biofarma's highest Days Sales Outstanding was 1039.14. The lowest was 10.16. And the median was 92.71.

CANF's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.545
* Ranked among companies with meaningful Days Sales Outstanding only.

Can Fite Biofarma's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Can Fite Biofarma Days Sales Outstanding Historical Data

The historical data trend for Can Fite Biofarma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Can Fite Biofarma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Days Sales Outstanding falls into.

Can Fite Biofarma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Can Fite Biofarma's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.743	*	365
=	0					/	0.743	*	365
=	0.00

Can Fite Biofarma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.155	*	365 / 4
=	0					/	0.155	*	365 / 4
=	0.00

Can Fite Biofarma (AMEX:CANF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Can Fite Biofarma Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).